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Steroid receptor coactivator-3 (SRC-3/
AIB1) is an oncogene frequently amplified
and overexpressed in breast cancers.
Here we report that SRC-3 interacts with
REGg, a proteasome activator known to
stimulate the trypsin-like activity of the
20S proteasome. RNAi knockdown and
gain-of-function experiments suggest that
REGg promotes SRC-3 protein degrada-
tion. Cellular levels of REGg expression af-
fect estrogen-receptor target-gene expres-
sion and cell growth as a result of its ability
to promote degradation of the SRC-3 pro-
tein. In vitro proteasome proteolysis assays
using purified REGg, SRC-3, and the 20S
proteasome reinforce these conclusions
and demonstrate that REGg promotes the
degradation of SRC-3 in a ubiquitin- and
ATP-independent manner. This work dem-
onstrates the first example of a physiologi-
cally relevant endogenous cellular target
for the REGg-proteasome complex. It also
highlights the fact that an alternative mode
of proteasome-mediated protein degrada-
tion, independent of the 19S proteasome
regulatory cap, targets the SRC-3 protein
for degradation.
INTRODUCTION
Steroid receptor coactivator-3 (SRC-3, also known as AIB1/
TRAM-1/ACTR/RAC-3/p/CIP) was initially identified as a
gene amplified and overexpressed in numerous human
breast cancer cell lines (Anzick et al., 1997) and belongs to
the SRC family of transcriptional coactivators, includingSRC-1 (Onˇate et al., 1995) and GRIP1/TIF2/SRC-2 (Voegel
et al., 1996). The SRC family of proteins interact with ste-
roid-hormone receptors and enhance receptor-dependent
transcription (McKenna and O’Malley, 2002). Targeted dis-
ruption of the SRC-3 gene inmice has revealed a proliferative
role for this coactivator in the mammary gland. In addition,
SRC-3/ mice display growth retardation and reduced
adult body size, probably due to impaired IGF-1 signaling
(Wang et al., 2000; Xu et al., 2000), pointing to a role for
SRC-3 as an integrator of estrogen and growth-factor signal-
ing pathways. Consistent with the central role that SRC-3
plays in the development of the mammary gland, overex-
pression of SRC-3 is detected in 50%–60% of breast tu-
mor specimens (Anzick et al., 1997; Bautista et al., 1998;
Bouras et al., 2001; List et al., 2001b; Murphy et al.,
2000). SRC-3 is rate limiting for estrogen-mediated growth
in MCF-7 human breast cancer cells, indicating that this co-
activator is specifically involved in the growth-promoting ac-
tions of estrogens (List et al., 2001a, Wu et al., 2004).
Recent transgenic breast cancer models (Torres-Arzayus
et al., 2004; Kuang, et al., 2004; Kuang, et al., 2005) and cel-
lular studies (Wu et al., 2004) affirm that SRC-3 is indeed an
oncogene. Overexpression of SRC-3 in transgenic mice
leads tomammary hypertrophy, hyperplasia, abnormal post-
weaning involution, and the spontaneous development of
malignant mammary tumors. In vitro analysis also substanti-
ates the role of SRC-3 in oncogenic transformation (Wu
et al., 2004) and in the growth of prostate cancer cell lines
(Zhou et al., 2003). SRC-3 overexpression has also been ob-
served in a variety of other cancers (Torres-Arzayus et al.,
2004).
Despite the extensive studies on SRC-3 function, factors
responsible for the regulation of SRC-3 protein levels in cells
remain largely unknown. Although on certain occasions the
levels of SRC-3 can be regulated at a transcriptional level
in cancer cells, we have found that the regulation of SRC-3
mRNA levels does not play a prominent role under non-
pathological conditions and that posttranslational regulation
such as phosphorylation of SRC-3 is a common mechanism
used to control the activity of this coactivator protein (Wu
et al., 2004). Previous studies have implicated the role of
the proteasome in SRC-3 turnover (Lonard et al., 2000,Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc. 381
2004; Shao et al., 2004; Yan et al., 2003). SinceSRC-3 is ac-
cepted as an authentic oncogene, factors which influence
cellular SRC-3 protein levels could be of great importance
in determining a tissue’s potential for growth and oncogenic
transformation. To further understand the molecular details
of SRC-3 degradation, we used immunoprecipitation and
mass spectrometry analysis to identify endogenous cellular
proteasome-pathway proteins that are associated with
SRC-3, revealing REGg as an SRC-3 interacting protein.
REGg (also known as PA28g, PSME3, or Ki antigen) be-
longs to the REG or 11S family of proteasome activators
that have been shown to bind and activate the 20S protea-
some based on their ability to promote the degradation of
model peptide substrates (Dubiel et al., 1992; Ma et al.,
1992). Of the three REG family members, REGa and REGb
subunits form a heteroheptameric complex, whereas
REGg forms a homoheptameric complex with a molecular
mass of 200 kDa (Rechsteiner and Hill, 2005). REGg is
found in worms, insects, and higher animals, whereas
REGa and REGb are found only in vertebrates (Masson
et al., 2001).
The REG family of complexes appears to have different
subcellular distributions, with REGg being primarily nuclear,
whereas REGa and b are found throughout the cell (Wojcik
et al., 1998). Distinct differences in the patterns of protea-
somal activation by the three REG subunits exist when as-
sessed in vitro using fluorescent peptide substrates. REGa
and b, in combination or alone, activate cleavage after basic,
acidic, and hydrophobic residues in small fluorogenic test
peptides. By contrast, REGg stimulates proteasomal hydro-
lysis of peptides with basic residues next to the fluorescent
leaving group (Li and Rechsteiner, 2001). Importantly,
REGg only has been characterized in terms of its ability to
degrade small peptide model substrates. Prior to this report,
its ability to target an endogenous cellular target protein has
not been reported, so the role of REGg in vivo remains largely
unknown.
Interestingly, REGg expression in ductal carcinoma has
been reported to be reduced 15.7-fold in comparison to nor-
mal breast tissue based on a recent SAGE (serial analysis of
gene expression) study of 25,157 transcripts expressed dur-
ing early breast carcinogenesis by comparing various normal
(661,863 tags) and 11 breast cancer SAGE libraries
(1,090,815 tags) (Abba et al., 2004). The coincidence of re-
duction in REGg expression and the overexpression of SRC-
3 in breast cancers prompted us to investigate whether
REGg could regulate SRC-3 coactivator protein stability.
Here, we present evidence that REGg associates with
SRC-3 in vitro and in vivo and is specifically involved in
SRC-3 protein degradation in mammalian cells. These ob-
servations are reinforced by in vitro proteasome assays using
purified REGg, the 20S proteasome, and SRC proteins,
which indicate that REGg can selectively promote degrada-
tion of SRC-3. Perturbation of REGg protein levels in cells re-
sults in alteration of estrogen receptor (ER) target-gene ex-
pression and estradiol (E2) mediated cell growth in breast
cancer cells, indicating that regulation of SRC-3 protein sta-
bility serves as a mechanism to control the expression level382 Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc.of this critical coactivator protein. Significantly, our findings
demonstrate a biological role for an alternative pathway for
proteasome-mediated protein degradation in controlling
the protein level of SRC-3, a critical regulator of cell growth.
RESULTS
REGg Is a Component of a Cellular SRC-3 Complex
To search for proteins regulating SRC-3 homeostasis, we
immunoprecipitated all three SRC-family complexes from
HeLa cell nuclear and cytoplasmic extracts using antibodies
generated in our laboratory. We analyzed these SRC-asso-
ciated proteins by mass spectrometry and identified a com-
ponent interacting only with SRC-3 and having an apparent
molecular mass of30 kDa as REGg (Figure 1A). Other pro-
teins associated with SRC family members identified in this
effort are published elsewhere (Jung et al., 2005).
We next determined whether the association between en-
dogenous REGg and SRC-3 could be observed in the estro-
gen-receptor-positive breast cancer MCF-7 cell line by
coimmunoprecipitation analysis. Using MCF-7 whole-cell ly-
sate, SRC-3 antibody but not a control IgG could immuno-
precipitate endogenous REGg (Figure 1B). Similarly, coim-
munoprecipitation analysis using FLAG-tagged SRC-1,
SRC-3, or b-globin revealed that REGg preferentially inter-
acts with SRC-3 in comparison to the other proteins tested
(Figure 1C). The interaction with SRC-3 also was observed
when GST-REGg was used to pull down in vitro-translated,
35S-labeled SRC-3 (Figure 1D). The capability of GST-REGg
to interact with SRC-3 but not SRC-1 or SRC-2 reiterates the
finding that REGg interacts preferentially with the SRC-3
member of the p160 family.
To identify the region of SRC-3 required for interaction with
REGg, we examined the ability of REGg to interact with five in
vitro-translated SRC-3 fragments described previously (Yi
et al., 2005). These fragments include the bHLH/PAS do-
main (aa 1–320), the Ser/Thr-rich region (aa 321–581), the
receptor interaction domain (RID, aa 581–840), the CBP/
p300 interaction domain (CID, aa 841–1080), and the do-
main that contains histone acetyltransferase activity (HAT,
aa 1081–1417). Reciprocal GST pull-down assays were per-
formed using REGg and each of these SRC-3 fragments.
Only the SRC-3 HAT domain interacted with REGg (Fig-
ure 1E and data not shown).
REGg Is Involved in SRC-3 Turnover
A recent study demonstrated that REGg interacts with and
enhances the proteolysis of the HCV (hepatitis C virus)
core protein (Moriishi et al., 2003); the fact that REGg inter-
acts specifically with SRC-3 prompted us to ask whether
REGg can promote the degradation of SRC-3 as well. To
test this hypothesis, we used RNA interference to knock
down the expression of REGg in the MCF-7 breast cancer
cell line. Reduction of REGg expression resulted in a 2- to
3-fold increase in SRC-3 protein levels when compared
with samples treated with a control siRNA (Figures 2A and
2C). The effect on SRC-3 stability is selective since
Figure 1. REGg in the SRC-3 Complex
(A) Immunoprecipitation of REGg with anti-SRC-3 antibody. Nuclear extract from HeLa cells was immunoprecipitated with an anti-SRC-3 antibody, and
a 30 kDa protein was excised from gels for mass spectrometry analysis. Arrows point to the bands representing SRC-3 and REGg.
(B) Interaction of endogenous SRC-3 and REGg in breast cancer cells. Cell lysates from MCF-7 cells were immunoprecipitated with anti-SRC-3 or control
IgG and detected by Western blotting as described in Experimental Procedures.
(C) Interaction between exogenous SRC-3 and endogenous REGg. 293T cells were transiently transfected with 2 mg of FLAG-SRC-3, FLAG-SRC-1, or
FLAG-globin construct as control. Total cell lysate was immunoprecipitated with anti-FLAG antibody, and associated REGgwas detected byWestern blot-
ting.
(D) SRC-3 and REGg interaction in vitro. GST-REGg and 35S-labeled, in vitro-translated SRC-1, -2, or -3 were incubated for four hours. The amount of SRC
proteins pulled down by GST beads was detected by autoradiography.
(E) REGg interacts with the HAT domain of SRC-3. Reciprocal GST pull-down experiments were performed to demonstrate the interaction between REGg
and SRC-3-HAT. GST protein was used as control. In all these GST pull-down assays, 10% of 35S-labeled proteins were loaded as input controls.estrogen-receptor and b-actin levels were not significantly
changed by siREGg (Figure 2A). Real-time (RT) PCR analysis
following RNA interference demonstrated that the increase
in SRC-3 protein is not due to changes at the SRC-3
mRNA level (see Figure S1 in the Supplemental Data avail-
able with this article online). The increase of SRC-3 also
was observed when REGg was knocked down in T47-D
breast cancer cells (Figure S2). In addition, we showed
that four independent siRNA preparations against REGg
led to similar reductions in REGg levels and elevations of
SRC-3 protein levels (Figure S3). The pool of siRNAs, individ-
ual REGg siRNAs, MG132 treatment alone, or a combination
of MG132 and siREGg resulted in similar levels of SRC-3 in
MCF-7 cells (Figure 2B). We knocked down REGg in 293
cells and observed effects similar to that seen in two breast
cancer cell lines (Figure S4), suggesting a role for REGg in
controlling SRC-3 protein levels in multiple cell lines.
Consistent with the specific interactions between REGg
and SRC-3, RNAi knockdown experiments revealed a sur-
prisingly functional specificity for REGg. Compared with
the nonspecific control siRNA, a knockdown using the indi-vidual siRNA #3 or a pool of siRNAs against REGg revealed
a significant effect on SRC-3 protein levels but not on
SRC-1, SRC-2, or ER levels (Figure 2C). These results indi-
cate that REGg-mediated protein degradation is quite selec-
tive, failing to promote detectable turnover of the two closely
related members of the SRC coactivator family or of ER.
To further characterize REGg-mediated downregulation
of SRC-3 in more detail, we tested the degradation kinetics
of SRC-3 in MCF-7 cells before and after RNA interference
knockdown of REGg. Pulse-chase experiments were per-
formed after siRNA treatment. Cells treated with negative
control siRNA displayed a rate of decay of SRC-3 similar to
that described previously (Lonard et al., 2004). In contrast,
cells exposed to siREGg alone or along with MG132 demon-
strated significantly slower rates of decay (Figure 3A), indi-
cating that regulation of SRC-3 stability is influenced by
REGg. MG132 was able to block the decay of SRC-3
more efficiently than siREGg, suggesting the potential for in-
volvement of other mechanisms for cellular SRC-3 degrada-
tion (Figure 3B). Nevertheless, taken together, our results
strongly suggest that REGg is involved in SRC-3 turnover.Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc. 383
Figure 2. REGg Is Involved in SRC-3 Turnover
(A) RNA interference of REGg results in elevated SRC-3. MCF-7 cells were transfected with siREGg or a control negative siRNA (siNeg). Endogenous
SRC-3, ER, REGg, or b-actin was detected by Western blotting. The asterisks in (A) and (C) indicate a nonspecific band migrating slightly faster than
REGg. Relative protein levels were quantitated and listed below each panel. Similar experiments were repeated at least five times; a summary of these re-
sults is shown in Figure S4B.
(B) Effect of proteasome inhibitor on SRC-3 turnover. 293 cells were transfected with a control siRNA (lanes 1 and 4), an individual siREGg (lane 2), or a pool
of siRNAs against REGg (lanes 3 and 5). MG132 was added as indicated (lanes 4 and 5) for 12 hr before sample collection. A summary of siREGg exper-
iments in 293 cells is shown in Figure S4B.
(C) Specificity of REGg effect on nuclear receptor cofactors. MCF-7 cells were transfected with siRNA as indicated. Cell extracts were immunoblotted with
different antibodies as indicated.Overexpression of REGg Enhances
SRC-3 Degradation
Conversely, we examined whether overexpression of REGg
could enhance SRC-3 degradation. We transfected either384 Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc.a REGg expression vector or an empty parent vector into
HeLa cells and examined the level of cotransfected FLAG-
SRC-3. Compared to cells transfected with empty vector
only, transfection of the REGg vector resulted in a significantFigure 3. Pulse-Chase Labeling of SRC-3
in MCF-7 Followed by RNAi
MCF-7 cells were treated with control siNeg,
siREGg, or siNeg and MG132. Cells were pulse
labeled with 35S-methionine and collected after
chase for indicated times. Equal amount of cell ly-
sate were immunoprecipitated with anti-SRC-3.
(A) The autoradiograph of the pulse-labeled
SRC-3.
(B) Quantitated graph of (A).
Figure 4. Exogenous REGg Accelerates the Turnover of SRC-3
(A) Analysis of REGg action by immunofluorescence. HeLa cells were cotransfected with a GFP expression vector and a REGg expression vector (4 mg,
upper panel). Endogenous SRC-3 (red color) was detected by immunofluorescence. Lower panel represents a control experiment where GFP expression
vector was cotransfected with an empty vector, pCDNA3.1.
(B) REGg alters cotransfected SRC-3 levels. HeLa cells were transiently transfected with 4 mg of REGg expression vector or equal molar amount of empty
vector along with 1 mg of FLAG-SRC-3 or SRC-1. Cell extracts were immunoblotted with different antibodies as indicated.
(C) Characterization of wild-type and mutant REGg stable cell lines. Tetracycline-inducible, wild-type REGg (293REG) or mutant (293REGmut) cell lines
were treated with a vehicle or tetracycline for 3 days after transient transfection of HA-tagged HCV core construct. Cells were collected for Western blotting
analysis using antibodies indicated.increase in REGg expression in HeLa cells, and the amount
of FLAG-SRC-3 protein present was concomitantly reduced
as detected byWestern blotting (Figure 4B). However, REGg
was not able to reduce the level of cotransfected FLAG-
SRC-1 (Figure 4B), indicating again that REGg selectively
affects SRC-3 steady-state levels.
Because of the usual unavoidable problem of incomplete
transfection in experiments such as shown in Figure 4B, we
performed additional immunofluorescence analysis of cells
overexpressing REGg. A green fluorescent protein (GFP) ex-
pressing vector was cotransfected with a REGg expression
vector or an empty vector into HeLa cells to focus attention
to cells that were successfully transfected. Cells coexpress-
ing a significant amount of both GFP and REGg displayed
lower SRC-3 levels as detected by immunofluorescence
with a deconvolution microscope (shown in red, Figure 4A,
upper panel), whereas cells cotransfected with the control
vector did not reveal a noticeable change in SRC-3 protein
levels (Figure 4A, lower panel). In combination, these gain-of-function experiments support our loss-of-function results
showing that REGg is involved in SRC-3 turnover.
To further understand the role of REGg in protein turnover,
we generated two different tetracycline-inducible 293 cell
lines that overexpress either REGg or a mutant form of
REGg that is unable to activate the proteasome (N151Y;
Zhang et al., 1998). As expected, induced overexpression
of REGg resulted in a reduction of SRC-3 in this cell line (Fig-
ure 4C). A control HCV core protein, a known REGg target
viral protein, was also significantly degraded by REGg
when transiently expressed in this cell line (Figure 4C). How-
ever, themutant REGg could not degrade SRC-3 or the HCV
core protein (Figure 4C), indicating that intact REGg is spe-
cifically involved in the degradation of these two proteins.
Since REGg interacts with the SRC-3 HAT domain, we
also tested to see whether the SRC-3 HAT domain is in-
volved in the protein turnover. A FLAG-tagged SRC-3
DHAT mutant was generated and overexpressed in HeLa
cells along with REGg or an empty vector. Compared withCell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc. 385
Figure 5. REGg Mediates SRC-3 Degra-
dation by the 20S Proteasome In Vitro
(A) REGg accelerates SRC-3 degradation by the
20S proteasome. Purified REGg, SRC-3, and
20S proteasome were incubated for the indi-
cated times. A fraction of the reaction was immu-
noblotted with anti-SRC-3. Similar reactions
were performed using purified ER or SRC-1 as
substrate.
(B) Proteasome inhibitor blocks REGg-mediated
protein turnover. Experiments were carried out
as described in Experimental Procedures except
that different concentrations of epoxomicin (Epox)
were simultaneously incubated with the mixture
of REGg and 20S proteasome as indicated.
(C) REGa/b or REGg monomer has no effect on
SRC-3. REGg, REGa/b, or REGg monomer
(GST-REGg) was incubated with purified SRC-3
and 20S proteasome for 45 min. SRC-3 levels
were detected by Western blotting.equal molar amounts of transfected wild-type SRC-3, the
mutant SRC-3 was resistant to REGg-mediated protein
turnover (Figure S5). This result suggests that the HAT do-
main of SRC-3 is required for its degradation by REGg.
REGg Promotes SRC-3 Degradation by the 20S
Proteasome In Vitro
To gain additional insight into the mechanism of REGg-me-
diated SRC-3 degradation, we examined the capacity of
REGg to direct cell-free proteolysis. Based on the propensity
for REGg to form heptamers spontaneously (Li et al., 2001),
we purified a bacterially expressed GST-REGg fusion pro-
tein, removed GST, and incubated the isolated REGgmono-
mers overnight at room temperature to allow for heptameric
complex formation. These REGg heptamers then were fur-
ther purified by gel filtration. Figure S6 shows the elution pro-
file of REGg from the gel filtration column with a peak in frac-
tion #45, corresponding to a protein complex of 200 kDa,
matching the expected size of the heptameric REGg com-
plex (Li et al., 2001).
To verify that our purified REGg heptamer was able to ac-
tivate the 20S proteasome appropriately, we first performed
a proteasome activation assay using fluorogenic peptides as
substrates. Since REGg only stimulates the trypsin-like activ-
ity of the 20S proteasome in vitro, a basic peptide (LRR-
MCA) was used as a substrate to test for its trypsin-like
activity; a hydrophobic peptide (LLVY-MCA) served as a neg-
ative control for substrate specificity in the in vitro assay.
Figure S7 demonstrates that, in the presence of the 20S pro-
teasome, purified REGg significantly stimulated the trypsin-
like activity of 20S proteasome in a concentration-depen-
dent manner, while little enhancement of chymotrypsin-like
activity was shown for the LLVY-MCA substrate. These re-
sults indicate that we were able to reconstitute a REGg hep-
tameric complex that can function appropriately in a cell-free
assay (Li and Rechsteiner, 2001).386 Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc.We then tested the ability of recombinant REGg to facili-
tate the turnover of full-length proteins by the 20S protea-
some.We used purified proteins generated from baculovirus
as substrates. Incubation of REGg alone with SRC-3,
SRC-1, or ER for 30 min or 60 min had no significant effect
on these protein substrates (Figure 5A, lanes 2 and 6, com-
pare to lanes 1 and 5), indicating that REGg is not capable of
degrading these substrates by itself. In this assay, a combi-
nation of REGg and the 20S proteasome promoted much
faster turnover of SRC-3 than did the 20S proteasome alone
(Figure 5A, lanes 3 and 7, compare to lanes 4 and 8). In con-
trast, REGg did not enhance the 20S proteasome degrada-
tion of purified SRC-1 or ER proteins, consistent with the re-
markable specificity of REGg in whole cells described above.
Our results demonstrated a ‘‘direct’’ role of REGg in degra-
dation of a large human protein through catalytic activation of
the 20S proteasome. Since this in vitro assay system con-
tains no exogenous ATP or components required for protein
ubiquitination, it is apparent that REGg-proteasome-medi-
ated protein degradation occurs in a manner distinct from
the canonical route of proteasome-mediated protein degra-
dation where proteins are covalently modified with polyubi-
quitin chains prior to their ATP-dependent destruction by
the proteasome.
To confirm that the REGg-proteasome-mediated protein
degradation occurred through the established proteolytically
active sites residing in the proteasome core, we incubated
the purified proteins in the presence or absence of the pro-
teasome inhibitor epoxomicin. Figure 5B demonstrates
that epoxomicin inhibited SRC-3 decay in the presence of
REGg and the 20S core proteasome in a dose-dependent
manner, substantiating a requirement for the 20S protea-
some in REGg-mediated SRC-3 turnover and reaffirming
that the well-characterized active sites present within the
core of the 20S proteasome were responsible for REGg-me-
diated SRC-3 degradation. Similar results were observed
using MG132 (data not shown).
Figure 6. REGg Level Affects Endogenous ER Target-Gene Expression
(A) REGg regulation of ER-dependent pS2 expression is mediated by SRC-3. MCF-7 cells transfected with control siRNA (lanes 3 and 4), siREGg (lanes 5
and 6), a combination of siREGg and siSRC-3 (lanes 7 and 8), or siSRC-3 alone (lanes 9 and 10) were inducedwith E2 (+) or vehicle () for 12 hr before being
collected for RNA preparation. RT-PCR was performed with specific primers for pS2. The results were normalized against cyclophilin transcripts, and sta-
tistical analysis revealed significant differences between siNeg- and siREGg-treated samples (*p < 0.01, lanes 4 and 6).
(B) REGg knockdown enhances SRC-3 recruitment to the pS2 promoter. MCF-7 cells treated with control siRNA (siNeg) or siREGgwere used for chromatin
immunoprecipitation assay. Immunoprecipitated pS2 promoter DNA fragments were quantitated by RT-PCR. The results were normalized to a PCR prod-
uct representing a cyclophilin intron sequence. Time-course patterns of ER recruitment to the pS2 promoter were indicated by a dotted line with open circle
(siREGg treated) and a line with solid circle (siNeg treated). The SRC-3 recruitment profiles were represented by a line with open triangle (siREGg treated)
and a dotted line with solid triangle (siNeg treated). Data in (A) and (B) are represented as mean ± SEM.Since REGa and b are homologous to REGg, we tested
whether the REGa/b heteroheptamers could affect SRC-3
turnover in vitro. Incubation of the REGa/b complex along
with 20S proteasome for 45 min did not result in significant
SRC-3 turnover, indicating that REGg is functionally distinct
from REGa/b. During the purification of the REGg complex,
we found that an intact GST-REGg fusion protein could not
form heptamers (data not shown) likely because the GST
moiety blocked the oligomerization of REGg. We were able
to utilize this intact GST-REGg fusion-protein monomer to
test its ability to promote SRC-3 degradation and assess
whether REGg heptamers were required to promote
SRC-3 degradation. Although GST-REGg still interacts
with SRC-3 in vitro (Figure 1D), GST-REGg was not able to
enhance SRC-3 degradation by the 20S proteasome (Fig-
ure 5C). Using this in vitro proteasome activation assay, we
demonstrated that the heptameric REGg complex is able
to selectively mediate SRC-3 degradation in a ubiquitin-
and ATP-independent manner.
Modulation of ER-Mediated Gene Expression
and Cell Growth by REGg
Based on our observation that REGg plays a central role in
regulation of SRC-3 levels at a posttranslational level, we
next investigated whether disruption of REGg expression af-
fects subsequent estrogen-dependent biological actions in
ER-positive MCF-7 breast cancer cells. MCF-7 cells treated
with control siRNA or siREGg were treated with E2, and ex-
pression of two estrogen-regulated genes, pS2 and cyclin
D1, was measured by quantitative RT-PCR. Upon treatment
with E2, pS2mRNA was significantly induced. Levels of pS2
mRNA remained the same in MCF-7 cells treated with con-trol siRNA, while pS2 mRNA levels increased 70% in
MCF-7 cells treated with siREGg (Figure 6A). Importantly,
cells treated with either siSRC-3 or a combination of siREGg
and siSRC-3 had a similarly reduced pS2 expression, indi-
cating that the biological action of REGg is mediated through
its effect on SRC-3 (Figure 6A). Similar results were obtained
when analogous studies were carried out with cyclin D1
(Figure S8).
To recapitulate the elevated pS2 gene expression that is
attributed to changes in SRC-3 levels secondary to REGg
depletion, we overexpressed SRC-3 in MCF-7 cells. A 2.5-
fold increase of SRC-3 level resulted in 75% higher expres-
sion of pS2 mRNA in the presence of E2 when compared
with the cells transfected with only empty vector (Figure S9).
This result, analogous to our observation in Figure 6A,
suggests that SRC-3 plays a greater role in ER signaling
when REGg is depleted. We then asked whether siREGg-
mediated SRC-3 elevation could result in increased SRC-3
recruitment to an ER target-gene promoter. Chromatin im-
munoprecipitation assays were performed at various inter-
vals after E2 induction. MCF-7 cells treated with control
siRNA or siREGg demonstrated a pattern for ER recruitment
similar to the pS2 promoter, while SRC-3 recruitment in cells
treated with siREGg was significantly higher than in the cells
treated with control siRNA at all time points examined
(Figure 6B). The increased recruitment of SRC-3 in the pres-
ence of siRNA against REGg was likely a reflection of its
higher steady-state levels in the cells. However, we could
not detect REGg recruitment to the pS2 promoter (data
not shown).
Since SRC-3 affects estrogen-mediated growth of MCF-7
cells and SRC-3 is a primary ER coactivator in mammaryCell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc. 387
Figure 7. The REGg Effect on Cell Growth Potential Can Be Mediated by SRC-3
(A) Negative controls for cell size measurement. MCF-7 cells treated with control siRNAs (siNeg or siSRC-2) were exposed to E2 for 36 hr. Forward scatter
intensity was measured by flow cytometry. Perfect overlap of the curves is shown between siNeg (pink) and siSRC-2 (blue) treated cells.
(B) REGg effect on E2-mediated cell growth. MCF-7 cells treated with control siRNA or siREGg followed by E2 induction were measured for cell size by
forward scatter intensity. Right shift of the curve representing cell size for siREGg treatment (pink) indicates an increased average size (X mean 542) versus
control siNeg treatment (blue, X mean 511).
(C) MCF-7 cell size alteration summarized in percentage. Note that both a combination of siREGg plus siSRC-3 and siSRC-3 alone reduced cell size
by 3%.
(D) REGg effect on E2-independent cell growth. Equal numbers of 293 host cells and the tetracycline-inducible, REGg-expressing 293 cells were seeded
into 96-well plates. Following 48 hr of tetracycline induction, cell proliferation was determined every 24 hr using a colorimetric assay described in the
Experimental Procedures section. Normalized results (amount of 490 nm absorbance) from three independent experiments were plotted. Statistical analysis
displayed significant differences between tetracycline-treated and nontreated REGg-overexpressing cells (represented by solid triangle and open triangle,
*p < 0.05). Data in (C) and (D) are represented as mean ± SEM.cells, we examined the potential role of REGg for influencing
SRC-3-mediated cell growth. MCF-7 cells treated with
siSRC-2 displayed no significant difference in cell size com-
pared with cells treated with control siRNA (Figures 7A and
7C), consistent with other reports that SRC-2 does not
play a role in breast cancer cell growth (Xu and Li, 2003).
In contrast, in the presence of E2, cells treated with siREGg
displayed a 6% increase in cell size as compared to cells
treated with control siRNA (Figures 7B and 7C), indicating
that enhanced levels of SRC-3 increase cell size as reported
previously (Zhou et al., 2003). This result also is consistent
with the reported increase in cell size in REGg knockout
MEF cells (Murata et al., 1999). In contrast, when SRC-3
was knocked down either in combination with REGg or
alone in MCF-7 cells, cell size was reduced by 3% or
4%, respectively, as demonstrated by the forward scatter in-
tensity measurements summarized in Figure 7C, indicating
that the REGg effect on E2-stimulated cell size is mediated
by SRC-3.388 Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc.SRC-3 functions in part through an estrogen-independent
effect on growth-factor signaling, as demonstrated by the
existence of a partial resistance to insulin-like growth factor
1 (IGF-1) in SRC-3-deficient mice (Kuang et al., 2004). The
results in SRC-3 knockout mice have been substantiated
by other reports that SRC-3 is required for IGF-1-induced
proliferation in cell culture (Oh et al., 2004; Zhou et al.,
2003). To further test the effect of REGg on this SRC-3 cell
biological function, we measured the effect of REGg overex-
pression on cell proliferation using our REGg-inducible sta-
ble cell lines. Although REGg overexpression did not have
a significant effect on cell growth in 10% serum (data not
shown), up to 25% growth reduction was observed when
cells were grown in stripped serum supplemented with
IGF-1 (Figure 7D). The parental host cells treated with or
without tetracycline showed no differences in cell prolifera-
tion. This result is consistent with the characterized role of
SRC-3 in the IGF-1 signaling pathway, indicating that the
regulation of SRC-3 by REGg also can impact an
estrogen-independent signaling event. To exclude the pos-
sibility that the growth defect is due to ectopic expression
of a ‘‘generally toxic’’ protein, we performed cell growth ex-
periments with the mutant REGg cell line (Figure 4C). No dif-
ferences were observed in the cell growth when the mutant
REGg was overexpressed or uninduced (Figure S10), indi-
cating that the growth effect in wild-type REGg-expressing
cells is indeed related to REGg catalytic function. Taken to-
gether, our results show that REGg can influence cell growth
through regulation of the steady-state levels of SRC-3 in dif-
ferent cellular contexts.
DISCUSSION
This study describes a unique proteasome-mediated mech-
anism responsible for SRC-3 degradation. Herein we have
established that SRC-3 is a biological target of the REGg-
proteasome machinery, and we provide evidence that this
proteasome regulator can mediate the turnover of a human
protein through a process independent from the canonically
established mechanism for proteasome-mediated protein
degradation via ubiquitination and the 19S proteasome acti-
vator. Consistent with previous reports that this proteasome
cap neither hydrolyzes ATP nor specifically interacts with
polyubiquitin chains, we see that REGg-proteasome-medi-
ated SRC-3 degradation is ubiquitin and ATP independent.
Importantly, the REGg-mediated protein degradation did
not generically degrade nuclear receptor and coactivator
proteins but was relatively specific for SRC-3. Our study con-
tains the initial experimental evidence for the involvement of
an ‘‘alternative’’ proteasome regulator in the degradation of
a physiologically relevant protein. As such, it is not currently
known how general REGg-proteasome-mediated protein
degradation will be.
Accumulated evidence has establishedSRC-3 as a central
coregulator in multiple signaling pathways. Nevertheless, lit-
tle is known about how the steady-state levels of this impor-
tant coactivator are regulated. Previous studies indicated
that SRC family proteins can be targets of the more estab-
lished ubiquitin-proteasome pathway (Lonard et al., 2000)
and are specifically targeted by E2 ubiquitin-conjugating en-
zymes in an in vitro degradation assay (Yan et al., 2003). In
our present study, however, degradation of SRC-3 by
REGg is shown not to require ubiquitin, indicating that
SRC-3 degradation can be mediated by both ubiquitin-de-
pendent and ubiquitin-independent proteasome pathways,
with the REGg-mediated pathway contributing to 40%–
50%of SRC-3 degradation inMCF-7 cells (based on estima-
tion from pulse-chase experimental results). Examples of
proteins that are degraded by the proteasome in both ubiq-
uitin-independent and -dependent manners are p53 and
p73 (Asher et al., 2005). Additionally, select other proteins
are suggested to be degraded by the proteasome in a ubiq-
uitin-independent manner (Orlowski and Wilk, 2003), indi-
cating that the proteasome is subject to a variety of regula-
tory mechanisms.
We believe that REGg is involved in the physiologic regu-
lation of cell proliferation and growth based on the observa-tions that REGg knockout mice display modest growth retar-
dation and that the lack of REGg in embryonic fibroblasts
impedesG1/S phase progression (Barton et al., 2004). How-
ever, it had been difficult to assign REGg’s observed in vitro
activity a clear biological role in living cells. Our observation of
REGg’s effect on cell growth s consistent with that of primary
cell cultures of REGg/ mouse embryonic fibroblasts
(Barton et al., 2004). Although SRC-3 plays a role in cell
growth, as shown here and as reported previously, we can-
not exclude the possibility that other unidentified REGg tar-
get proteins contribute in part to REGg’s effect on cell
growth. The moderate overall growth retardation observed
in REGg knockout mice does not comply with what is ex-
pected, given REGg’s role in promoting SRC-3 degradation
(Barton et al., 2004). This is likely due to several possibilities.
First, more than one pathway is likely involved in SRC-3 turn-
over. In addition, it is probable that REGg also targets some
other proteins that are involved in modulating growth and
that the REGg/SRC-3 pathway has a positive effect in only
a restricted number of cell types. Differential regulation of
cell growth by REGg also was observed in our study. For ex-
ample, growth inhibition by overexpression of REGg in 293
cells was observed in the presence of IGF-1 but not in
10% serum medium, indicating that the growth-inhibitory
actions of REGg could be restricted to particular environ-
ments where SRC-3 function is most important.
Our examination of REGg in breast cancer-derived cells
affirms that REGg plays an important role in modulating
the expression of SRC-3; its loss results in higher SRC-3
protein levels, increased ER-mediated transcription, and en-
hanced E2-induced cell growth. This effect is likely mediated
by SRC-3 since coordinate depletion of SRC-3 abolished
both REGg-modulated gene expression and the effect of
REGg on cell size. Therefore, we speculate that REGg nor-
mally controls SRC-3 protein levels through the proteasome
machinery in breast tissue. Overexpression of SRC-3 in
a large percentage of breast cancers highlights the potential
for REGg to play a suppressive role in carcinogenesis since
our study provides evidence that SRC-3 protein overexpres-
sion can occur in part as a consequence of the reduced abil-
ity of the cell to degrade this protein.
Our experiments demonstrated that REGg enhances 20S
proteasome-mediated degradation of SRC-3 in vitro in
a ubiquitin- and ATP-independent manner. ATP normally is
required for degradation of ubiquitinated proteins by the pro-
teasome. Although we still don’t fully understand the precise
biochemical mechanisms involved in REGg-mediated pro-
tein turnover that explain this paradox, we can only speculate
that the REGg-20S proteasome system may be a Brownian
ratchet that is able to rectify thermal vibrational forces into
a propulsion mechanism that can drive a protein substrate
entirely through the proteasome (Bar-Nahum et al., 2005;
Saffarian et al., 2004). By this theory, the initial direct interac-
tion between SRC-3 and REGgmay function as a ratchet to
prevent the backward movement of the substrate molecule
within the 20S proteasome channel, allowing for efficient
degradation of the SRC-3 protein. Although ATP is not
used in this system, free energy could be provided byCell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc. 389
concurrent peptide hydrolysis. Examples also exist where
unstructured proteins can be effectively degraded by the
20S proteasome (Liu et al., 2003). It is possible that SRC-3
can be effectively degraded due to its unstructured nature
as well, obviating the need for the ‘‘reverse chaperone’’ ac-
tivity normally provided by the ubiquitin-dependent 19S pro-
teasome regulatory particle and its requisite ATPase activity.
In conclusion, we have provided molecular evidence that
the alternative proteasome regulator, REGg, controls the
turnover of SRC-3 in vivo and in vitro. Because SRC-3 is
an oncogenic molecule clearly involved in the development
and progression of breast cancer, it would be expected
that important checks on its expression might exist at multi-
ple levels in the cell. In addition to dysregulation at the level of
gene amplification and mRNA overexpression, we show
here that this important integrator of nuclear receptor signal-
ing also is subject to regulation at the level of protein stability
through a noncanonical means of proteasome-mediated
protein degradation. Furthermore, we believe this to be
a mechanism that is intimately involved in the normal cellular
physiology of coactivators. With respect to this point, REGg
could serve as a tumor suppressor through its role in nega-
tively regulating SRC-3 levels and function in breast tissue.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
HeLa (ATCC, Rockville, MD), MCF-7 (Richard Santen, University of
Virginia), and other cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% v/v FCS and 100 mg/ml penicillin/streptomy-
cin. T47-D cell (Dr. Jack-Michel Renoir, France) was maintained in
0.2 mg/ml Geneticin (Invitrogen). MG132 was prepared as a 1 mM stock
solution dissolved in DMSO. Cycloheximide was dissolved in ethanol. An
affinity-purified anti-SRC-3 (BL438) was generated at the Bethyl Labora-
tory (Montgomery, TX) by immunizing rabbits with purified synthetic pep-
tides. Anti-SRC-1 and anti-SRC-2 were used as previously described
(Li et al., 2003). REGg antibody was purchased from Zymed (Cat. # 38-
3800; CA). Anti-FLAG and anti-b-actin were purchased from Sigma
(Cat. # F3165 and A5441, respectively; MO). All the experiments were re-
peated two to five times in independently conducted experiments.
Preparation of Nuclear Extract, Immunoprecipitation,
and Mass Spectrometry
HeLa nuclear extract was prepared as previously described (Dignam
et al., 1983; Jung et al., 2005). For immunoprecipitation of SRC-3-asso-
ciated protein, the frozen nuclear extract was thawed on ice and cleared
by centrifugation at 100,000 g for 15 min at 4ºC. About 10 mg of super-
natant was mixed with 20 mg of affinity-purified SRC-3 antibodies and ro-
tated for 4 hr at 4ºC. The mixture was then centrifuged at 15,000  g for
20 min at 4ºC. The cleared supernatant was mixed with 40 ml of protein
A-Sepharose beads (a 50% slurry) and rotated for 1 hr at 4ºC. The immu-
noprecipitates were washed three times with NETN buffer (20 mM Tris-
HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% NP-40). The washed
beads were boiled with Laemmli buffer and subjected to SDS-PAGE
(4%–20% Tris-glycine ready gel, Invitrogen). For a smaller scale of immu-
noprecipitation in Figures 1B and 1C using cell extract from MCF-7 or
293T cells, cells were treated with DSP crosslinking reagent following
the manufacturer’s instruction (Pierce, IL). Immunoprecipitates were re-
verse crosslinked by b-mercaptoethanol before being resolved by SDS-
PAGE. Mass spectrometry was performed as described previously
(Jung et al., 2005).390 Cell 124, 381–392, January 27, 2006 ª2006 Elsevier Inc.Generation of Plasmid Constructs
A human REGg cDNA was generated by RT-PCR with the primers for-
ward: 50-CACCATGGCCTCGTTGCTGAAGG-30 and reverse: 50-TCA
GTACAGTGTCTCTGCATTGCTG-30 and was inserted into pcDNA3.1-
TOPO/D-V5-HIS (Invitrogen). The N-terminal GST-REGg fusion was cre-
ated by PCR using the primers forward: 50-CGAATTCATGGCCTCGTTG
CTGAAG-30 and reverse: 50-CATCTCGAGTCAGTACAGTGTCTCTGC-30
and insertion into EcoRI/XhoI of pGEX-4T-1 (Amersham Biosciences). All
of the constructs were verified by DNA sequencing.
GST Pull-Down Assay
GST-REGg and GST fusion proteins for SRC-3 subfragments were ex-
pressed in Escherichia coli BL21 (Stratagene) and were purified by using
glutathione Sepharose affinity chromatography. The TNT-coupled tran-
scription-translation system (Promega) was used to produce 35S-methio-
nine-labeled REGg and SRC proteins. For each GST pull-down experi-
ment, about 100 ng of fusion protein was incubated with 5–10 ml of in
vitro-translated protein in binding buffer (50 mM Tris-HCl [pH 7.5],
200 mM NaCl, 10% glycerol, 1% NP-40, 1 mM DTT plus protease inhib-
itor cocktail). After extensive washes with the same buffer, bound proteins
were resolved by SDS-PAGE and detected by autoradiography.
RNA Interference and Western Blot Analysis
All siRNA duplexes were purchased from Dharmacon (Lafayette, CO). For
each RNA interference experiment, cells were prepared at 60% conflu-
ence 1 day before transfection. Ten nanomolar quantities of each siRNA
were transfected into cells with TransIT-TKO reagents from Mirus (Mad-
ison, WI) following the manufacturer’s instruction. Cells were harvested
4 days after transfection and corresponding inductions. Cell extracts
were resolved in 4%–15% gradient SDS gels and transferred to nitrocel-
lulose membranes (Bio-Rad). Following incubation in blocking buffer
(50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% Tween 20, and 5% nonfat
milk), membranes were incubated with diluted primary antibodies over-
night at 4ºC with gentle shaking. Following extensive washes and sec-
ondary antibody incubation, specific binding was visualized by chemilu-
minescence (Amersham Biosciences).
Metabolic Labeling of Cell Proteins
Cells treated with appropriate siRNA for 4 dayswere used for pulse-chase
labeling experiments as previously described (Yi et al., 2005).
Protein Purification and In Vitro Proteolytic Analysis
To generate REGg heptamers, GST-REGg bound to glutathione beads
was cleaved by thrombin in PBS (pH 7.2) at room temperature overnight.
Following removal of thrombin by p-aminobenzamidine agarose (Sigma),
the supernatant was concentrated with a Centricon YM-50 column (Milli-
pore, MA). Collected samples were then loaded onto a Superose 6 gel fil-
tration column (Amersham Biosciences, 10 mm  30 cm) pre-equili-
brated with running buffer (20 mM HEPES [pH 7.5], 100 mM KCl,
0.5 mM EDTA, and 10% glycerol) at a flow rate of 0.5 ml/min.
Recombinant SRC-3 protein was produced from baculovirus-infected
Sf9 cells using the Bac-to-Bac system (Invitrogen). To ensure the pres-
ence of full-length protein, His6 and FLAG sequences were tagged to
the N terminus and C terminus of recombinant SRC-3 protein, respec-
tively. The protein was purified by standard nickel-NTA chromatography
(QIAGEN) followed by FLAG M2 (Sigma) affinity chromatography accord-
ing to the manufacturer’s instructions. Recombinant SRC-1 protein was
a gift from Dr. Steven Nordeen, and ERa was a gift from Dr. Dean Ed-
wards. The purified 20S proteasome was purchased from Boston Bio-
chem.
Fluorogenic peptide assays were performed by incubating various
amounts of REGg, 20 nM of fluorogenic peptide (LLVY-MCA or LRR-
MCA), and 0.25 mg of the 20S proteasome for 30 min at room tempera-
ture in 100 ml PBS buffer. The reactions were stopped by adding equal
amount of ethanol, and fluorescent signals were measured by an ISS
PC1 fluorometer. For large protein substrates, 20 ng of protein sub-
strate was incubated with 0.25 mg of 20S proteasome and 1 mg of
REGg heptamers for the indicated times in 100 ml reaction buffer (20 mM
HEPES [pH 7.5], 100 mM KCl, 0.5 mM EDTA, and 10% glycerol) at 30ºC.
Experiments in Figures 5B and 5C were performed using 20S protea-
some purchased from Affinity Bioregents, which has less degrading ability
by itself. In vitro assay conditions were the same as described above, ex-
cept that mixtures were incubated at 37ºC for 45 min. An aliquot of the
reaction was analyzed by Western blotting.
Chromatin Immunoprecipitation Assay and Real-Time
Quantitative PCR
Chromatin immunoprecipitation was performed as previously described
(Li et al., 2003). The DNA was quantitated by real-time quantitative PCR
using pS2 promoter-specific primers (forward, 50-CGTGAGCCACTG
TTGTCAGG-30; reverse, 50-TGGTGAGGTCATCTTGGCTG-30; TaqMan
probe, 50-FAM-CAAGCCTTTTTCCGGCCAT-TAMRA-30). The results
were normalized to PCR product amplified with a pair of cyclophilin intron
3-specific primers (forward, 50-TGTTTAATGACATTTAGTACAAAAGGCT
TC-30; reverse, 50-GAACAACATTATGACTGGCAACC-30; probe, 50-FA
MAGCTACCTTTCTCGTCTTG-TAMRA-30). Real-time PCR reactions
were performed using the AIB Prism 7700 sequence detection system
(Applied Biosystems). RT-PCR analysis of endogenous pS2 mRNA was
performed as described before (Lonard et al., 2004). To avoid variations
from different samples, the relative pS2 mRNA levels were normalized
against cyclophilin mRNA content of the same sample.
Transient Transfection, FlowCytometry, and Statistical Analysis
Transfection of plasmids was performed using Fugene 6 reagent (Roche)
following the manufacturer’s instructions. Cells subjected to cell growth
studies were treated with corresponding siRNA in 5% stripped FCS. After
E2 (108 M) stimulation for 36 hr, cells were collected to measure forward
scatter intensity by flow cytometry. Statistical analysis was performed as
previously described (Li et al., 2003).
Generation of the REGg-Inducible Stable Cell Line
and Determination of Cell Differentiation
A stable cell line overexpressing REGg was generated in a 293 cell line in
which the integrated Flp-In-T-Rex system contains a single FRT site and
stably expresses Tet repressor for convenient creation of Tet-inducible
REGg-expressing cell lines. REGg cDNA was inserted into HindIII and
XhoI linearized pcDNA5/FRT/TO expression vector and transfected into
Flp-In-293 host cells following the manufacturer’s instructions (Invi-
trogen). To determine IGF-1-dependent cell growth, the inducible
REGg-expressing cells and host cells were seeded in 96-well plates at
the concentration of 2500 cells per well. IGF-1 was added at 100 mg/ml
in 5% stripped medium. Following 48 hr of tetracycline induction at
1 mg/ml, cell growth was determined daily with the CellTiter 96 AQueous
Non-Radioactive Cell Proliferation Assay (Promega).
Immunofluorescence
Transfected HeLa cells were fixed, permeabilized, and immunoblotted as
described previously (Stenoien et al., 2000). Deconvolution microscopy
was performed with a Zeiss Axiovert S100 TV microscope and a Delta-
Vision Restoration Microscopy System (Applied Precision, Inc.). Z series
focal planes were digitally imaged and deconvolved with the DeltaVision
constrained iterative algorithm. All image files were digitally processed
for presentation with Adobe Photoshop.
Supplemental Data
Supplemental Data include ten figures and can be found with this article
online at http://www.cell.com/cgi/content/full/124/2/381/DC1/.
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